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Abstract
Background: Substantial evidence suggests that high glucose (HG) causes endothelial cell damage; however, the
potential mechanism therein has yet to be clarified. The aim of this study was to investigate the influence of HG
on the endothelial-to-mesenchymal transition (EndMT) and its relevance to the activation of the renin-angiotensin
system.
Methods: Primary human aortic endothelial cells (HAECs) were divided into three groups: a normal glucose (NG)
group, HG group, and irbesartan (1 μM)-treated (HG+irbesartan) group. The concentration of angiotensin II in the
supernatant was detected by radioimmunoassay. Pathological changes were investigated using fluorescence
microscopy and electron microscopy. Immunofluorescence staining was performed to detect the co-expression of
CD31 and fibroblast markers, such as fibroblast-specific protein 1 (FSP1). The expressions of FSP1 and a-SMA were
detected by RT-PCR and Western blot.
Results: The treatment of HAECs in the HG group resulted in significant increases in the expressions of FSP1 and
angiotensin II in dose-and time-dependent manners. The incubation of HAECs exposure to HG resulted in a
fibroblast-like phenotype, wherein increased microfilamentation and a roughened endoplasmic reticulum structure
were observed in the cytoplasm. The expressions of FSP1 and a-SMA were significantly increased in the HG group,
and these changes were inhibited by irbesartan treatment (P < 0.05). Double staining of the HAECs indicated a co-
localization of CD31 and FSP1 and that some cells acquired spindle-shaped morphologies and a loss of CD31
staining; however, treatment with irbesartan attenuated the expression of EndMT (P < 0.05).
Conclusions: These findings suggest a novel mechanism in HG-induced endothelial damage via the mediation of
the EndMT by angiotensin II, which was inhibited by Irbesartan.
Background
Vascular complications, such as cardiomyopathy and
nephropathy, are the leading cause of morbidity and
mortality in patients with diabetes. Because the initial
injury by hyperglycemia occurs in the blood vessels,
endothelial cells are considered to be the first target,
and, furthermore, endothelial damage plays an impor-
tant role in the development and progression of diabetic
vascular complications [1-3]. Four main molecular
mechanisms have been implicated in glucose-mediated
vascular disease: the glucose-induced activation of
protein kinase C isoforms, an increased formation of
glucose-derived advanced glycation end-products
(AGEs), an increased glucose flux through the aldose
reductase pathway, and an increased production of reac-
tive oxygen species [4]; however, the mechanisms of
endothelial injury by high glucose (HG) are not fully
understood.
Recent studies have indicated that the endothelial-to-
mesenchymal transition (EndMT) could contribute to the
progression of diabetic nephropathy, diabetic renal fibro-
sis, and cardiac fibrosis [5-7], and that the rennin-angio-
tensin system (RAS) may be involved. Irbesartan is an
angiotensin II (Ang II) receptor type 1 blocker (ARB) and
has been shown to reduce vascular endothelial damage,
improve hyperglycemia-induced endothelial dysfunction,
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blasts in valve leaflets [8-11]. The aim of this study was to
explore the influence of HG on the EndMT and its rele-
vance in the activation of the RAS in HAECs.
Materials and methods
Cell culture
HAECs were purchased from Sciencell (No. 6100) and
grown in a Sciencell endothelial basal medium (ECM,
No. 1001). This ECM consists of 500 ml of basal med-
ium, 25 ml of fetal bovine serum (No. 0025), 5 ml of
endothelial cell growth supplement (No. 1052), and
5 ml of a penicillin/streptomycin solution (No. 0503).
Cells were cultured at 37°C in a humidified atmosphere
with 5% CO2. The medium was changed every other day
until the culture was approximately 50% confluent.
When the culture reached 50% confluence, the medium
was changed every day until the culture was approxi-
mately 80% confluent. HAECs were performed between
the 2-4 passages. The culture medium was changed to a
serum-free solution for 24 h, and the HAECs were trea-
ted with normal glucose (NG; 5.5 mM), HG (15 mM or
30 mM D-glucose) [12], or 5.5 mM NG + 24.5 mM man-
nitol for 48 h. These cells were exposed to HG (media
that contained 5.5, 15, or 30 mM D-glucose) for 0, 6, 12,
24, 48, and 72 h. Some of the cells that were exposed to
HG (30 mM) were also incubated with irbesartan (1 μM,
Sanofi-aventis, France) [13] for 48 h.
Ang II measurement
Ang II was measured in the supernatant by radioimmu-
noassay, as previously described [14]. A commercial
radioimmunoassay kit (Beifang, China) was used for the
Ang II measurement. On the basis of the time course of
Ang II synthesis, HAECs were exposed to HG (30 mM)
for 48 h.
RT-PCR analysis
Total RNA was prepared from the HAECs using TRIzol
(Key GEN). Total RNA was prepared using TRIzol (Key
GEN) from HAEC. PCR reactions were performed
using specific primer pairs: a FSP1 sense primer: 5′
TTGGGGAAAAG GACAGATGAAG 3′, anti-sense pri-
mer: 5′TGAAGGAGCCAGGGTGGAAAAA 3′), a-SMA
sense prime: 5′ATAACATCAAGCCCAAATCTGC3′,
anti-sense primer: 5′ TTCCTTTTTTCTTTCCCAACA
3’) and a GADPH sense primer: 5′AAGGTCG GAGT-
CAACGGATTT 3′, antisense primer: 5′AGATGAT-
GACCCTTTTGGCTC 3′).
Western blot analysis
Equal amounts of cell lysate proteins (30 μg) were sepa-
rated on 4-20% SDS-polyacrylamide gels and transferred
onto nitrocellulose membranes (Pall, USA).
The membranes were incubated overnight with poly-
clonal rabbit anti-rat FSP1 and the polyclonal rabbit
anti-rat a-SMA (Abcam, England), followed by a horse-
radish peroxidase-labeled goat anti-rabbit IgG (Key
GEN, China). The signals were detected using an ECL
advance system (GE Healthcare, UK).
Immunofluorescent Staining
For a double immunofluorescence procedure, we incu-
bated the HAECs with two primary antibodies at 4°C
overnight. The primary antibodies were monoclonal
mouse anti-CD31 (Santa Cruz Biotechnology, Europe)
and polyclonal rabbit anti-FSP1 (Abcam, England). We
incubated cells in 1% BSA for 1 h at room temperature
in the dark with a mixture of two secondary antibodies
and two different fluorochromes: Rhod red-conjugated
goat anti-rabbit and FITC green-conjugated goat anti-
m o u s e .A san e g a t i v ec o n t r o l ,t h ep r i m a r ya n t i b o d yw a s
replaced with non-immune IgG, and no staining could
be observed. FSP1
+ cells were observed to have oval and
elongated shapes in the HG group. The pictures were
captured by the LSM5 image browser (Zeiss) and ana-
lyzed using a laser scanning confocal microscope (LSM
510 META, Zeiss).
Morphological analysis
Ultra-thin cells were counter-stained with uranyl acetate
and lead citrate and were examined with a transmission
electron microscope (HITACHI H600, TEM). The
LSM5 image browser (Zeiss) was used to capture images
of morphological changes in the HAECs using CD31
immunofluorescence staining, as previously mentioned.
Statistical analysis
Data were expressed as mean ± standard deviation (SD)
and analyzed by one-way analysis of the variance
(ANOVA) using SPSS, version 13.0. Data were consid-
ered significant if P < 0.05.
Results
HG exposure dose response and time course on HAEC
angiotensin II production
To demonstrate that enhanced Ang II production
depended on the concentration and duration of HG
exposure, we incubated HAECs in a medium that con-
tained 5.5, 15, or 30 mM glucose for 48 h. Mannitol was
added to the control cell incubation medium to equalize
the osmolarity. Ang II was observed to increase in a
dose-dependent manner in response to HG exposure
(Fig. 1A). The concentration of Ang II in HG-exposed
cells (30 mM) increased as early as 12 h and continued
to increase until 48 h after exposure (Fig. 1B). As can be
observed in Fig. 1C, irbesartan partially inhibited Ang II
production in the culture medium.
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A ss h o w ni nF i g .2 ,F S P 1a n da-SMA mRNA expres-
sions in HAECs exposure to HG were markedly up-
regulated in comparison to NG group, which were
inhibited by treatment with irbesartan (P < 0.05).
The effect of irbesartan on the protein expression of FSP1
and a-SMA
According to Fig. 3A-B, after exposing a confluent mono-
layer of cells with HG at different concentrations and
periods of time, it can be observed that after 48 h of
exposure to increased HG concentrations, the FSP1 pro-
tein was progressively up-regulated (NG 5.5 mM: 0.08 ±
0.01, HG 15 mM: 0.57 ± 0.04, HG 30 mM: 1.25 ± 0.06;
#P <0 . 0 5v s .N G ) ,r e a c h i n gap e a ka t3 0m MH Gw i t ha
15.62-fold increase in comparison to that with NG expo-
s u r e( F i g .3 A ) .I nr e s p o n s et o3 0m MH G ,t h ei n t r o d u c -
tion of HG time-dependently induced the synthesis of
FSP1 protein (0 h: 0.04 ± 0.001, 12 h: 0.652 ± 0.04, 24 h:
0.98 ± 0.04, and 48 h: 1.22 ± 0.02; P <0 . 0 5v s .t h ec o n -
trol; Fig. 3B). Furthermore, FSP1 and a-SMA protein
expression in HAECs exposure to HG were markedly up-
regulated in comparison to NG group, which were inhib-
ited by treatment with irbesartan (P < 0.05).
Confocal microscopic analysis
We performed labeling experiments using antibodies to
CD31 (endothelial cell marker; green) and fibroblast
markers FSP1 (red, also termed S100A4). Confocal
microscopy revealed the co-localization of both FSP1
and CD31 (Fig. 4B). An analysis of FSP1/CD31 double
labeling revealed that some cells acquired FSP1 staining
and lost CD31 staining, which suggests that the EndMT
occurred. The administration of irbesartan markedly
reduced the number of such double-staining cells (Fig.
4C, P < 0.05). In the control cells, FSP1 expression was
confined to sparsely scattered fibroblasts (Fig. 4A).
Morphological analysis
Normal endothelial monolayers displayed a typical cob-
blestone morphology. We observed that HAECs
Figure 1 The dose and time dependency of HG-stimulated
Ang II synthesis in HAECs. A: HAECs grown in a culture medium
consisting of 5.5 mM, 15 mM, or 30 mM glucose for 48 h.
Mannitol was used as a control for hyperosmolarity. B: HAECs
grown in a 30 mM glucose medium for 6-72 h. Ang II was
measured in the supernatant using radioimmunoassay. C: High
glucose stimulated Ang II synthesis in the supernatant in the
absence or presence of irbesartan in HAECs. HAECs that were
grown in a serum-free normal glucose medium (NG, 5.5 mM) for
24 h and exposed to high glucose (HG, 30 mM) or in 5.5 mM
glucose + 24.5 mM mannitol (NG+M) in the absence or presence
of 1 μM irbesartan for 48 h. Irbesartan partially inhibited Ang II
production in the culture medium. The depicted values are the
means mean ± SD from three independent experiments that were
performed in duplicate. # P < 0.05 vs. mannitol (A) or NG (B). *P <
0.05 vs. HG without inhibitor.
Figure 2 The effect of irbesartan on the mRNA expression of
FSP1 and a-SMA.
#P < 0.05 vs. NG. and *P < 0.05 vs. HG. NG:
normal glucose. HG: high glucose. HI+Irb: high glucose + Irbesartan.
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with cells becoming elongated, spindle-shaped and lost
cobblestone morphologies according to fluorescence
microscopic analysis (Fig. 5B). Interestingly, treatment
with irbesartan was observed to significantly prevent
these morphological changes (Fig. 5C).
Electron microscopy analysis of the control demon-
strated that the endothelial cells therein exhibited
normal structures (Fig. 6A, × 6000). In contrast, the HG
group that was treated with HG (30 mM) for 48 h
exhibited endothelial protrusion, a significantly rough-
ened endoplasmic reticulum, and microfilamentation
(arrows, Fig. 6B, × 6000). These changes were attenu-
ated by treatment with irbesartan (Fig. 6C, × 6000).
Discussion
Microangiopathy is the most common complication in
diabetes, wherein endothelial cell injury is an early fea-
ture of microvascular lesions. Studies have shown that
endothelial injury accelerates atherosclerosis and subse-
quently causes cardiovascular events [15]. Emerging evi-
dence has shown that hyperglycemia may have a direct
role in endothelial cell injury [16-18], which is charac-
terized by cell apoptosis. More recently, it has been
shown that the endothelium may develop the EndMT,
which has been found to be involved in cardiac fibrosis
and tubulointerstitial fibrosis in animal models
[6,7,19,20]; however, the potential mechanisms therein
are still largely assumptive. In this study, we found that
when HAECs were exposed to HG, they developed a
series of phenotypical changes, such as a spindle-shaped
morphology, an increasingly roughened endoplasmic
reticulum, and microfilamentation. Moreover, these cells
expressed FSP1 and a-SMA, which suggests the occur-
rence of the EndMT.
Although the EndMT was first investigated as a criti-
cal process in heart development [21], it is now clear
that the EndMT can also postnatally occur in various
pathological settings, including cardiac fibrosis, renal
fibrosis, and diabetic nephropathy. Recent studies have
shown that the EndMT also contributes to the develop-
ment of diabetic renal interstitial fibrosis, diabetic
nephropathy, and cardiac fibrosis [5,7,19], which indi-
cate a relationship between the EndMT and fibrosis.
Cardiac and renal fibroses are also the most common
diabetic vascular complications [22-24]. Chronic hyper-
glycemia is a major initiator of diabetic vascular compli-
cations. Indeed, HG via various mechanisms, such as an
increased production of oxidative stress, AGEs, and the
activation of the RAS and protein kinase C [4,25], pro-
motes cardiac and renal fibroses. Therefore, whether
HG directly induces the EndMT in HAECs is an inter-
esting question that has not been previously addressed.
In this study, our findings demonstrate that double-
stained HAECs exposure to high glucose exhibited the
co-localization of CD31 and FSP1, and some cells
acquired spindle-shaped morphologies and a loss of
CD31 staining. Furthermore, the expressions of FSP1
and a-SMA were significantly increased in the HG
group, which strongly indicates an HG-induced EndMT
and could be an important mechanism in diabetic vas-
cular complications.
Figure 3 Western blot analysis of the effect of HG on the
synthesis of FSP1 and a-SMA protein in HAECs. A: HAECs were
grown in a culture medium that contained 5.5-30 mM glucose for
48 h. Mannitol was used as a control for hyperosmolarity. B: HAECs
were incubated with HG (30 mM) for 0, 12, 24, and 48 h. (0 h: 0.04
± 0.001, 12 h: 0.65 ± 0.04, 24 h: 0.98 ± 0.04, and 48 h: 1.22 ± 0.02;
#P < 0.05 vs. the control). C: Western blot analysis of the effect of
HG on the synthesis of a-SMA and FSP1 protein in HAECs. Values
are means ± SD;
#P < 0.01 vs. NG and * P < 0.05 vs. HG. NG: normal
glucose. HG: high glucose. HI+Irb: high glucose + Irbesartan.
Experiments were repeated three times. Irb: Irbesartan
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observed that irbesartan as an ARB significantly inhib-
ited the EndMT. Furthermore, other studies have
demonstrated the antiproteinuric effects and the preser-
vation of endothelial function that derive from ARB,
which translate into cardiovascular and renoprotective
benefits that extend beyond the lowering of blood pres-
sure [26,27]. In vitro and in vivo studies have found that
irbesartan could ameliorate endothelial function in
hypertension and diabetes, which are two frequent dis-
eases where endothelium homeostasis alterations are
typically present [27]. In addition, irbesartan therapy has
been demonstrated to improve metabolic risk factors in
clinical settings [28,29]; however, the exact mechanisms
of the cardiovascular and renoprotective benefits that
derive from irbesartan therapy are not fully understood.
In this study, we found that HG directly stimulated
angiotensin II synthesis in HAECs, and irbesartan mark-
edly protected endothelial cells from HG-induced injury.
Because the EndMT may be an early event in the patho-
genesis of fibrosis [19,30], our findings suggest that early
treatment with ARB might be an important strategy in
the prevention of microvascular disease that is compli-
cated by diabetes.
Figure 4 Irbesartan inhibited the high glucose-induced EndMT in HAECs according to laser-scanning confocal microscopy.
Representative immunofluorescence staining of CD31 (green) and FSP1 (red) were observed. A merging of both images reveals populations of
cells acquired FSP1 expression and lost CD31 expression (arrows, B). The administration of irbesartan reduced the number of co-localization of
CD31 and FSP1 (C, P < 0.05). A: normal glucose as controls; B: Treated with HG (30 mM) for 48 h. C: Treated with HG (30 mM) + irbesartan
(1 μM) for 48 h. Experiments were repeated three times. NG: normal glucose. HG: high glucose. HI+Irb: high glucose + Irbesartan.
Figure 5 Immunofluorescence staining of HAECs with CD31 in various groups. The Incubation of HAECs with high glucose (30 mM) for
48 h resulted in a fibroblast-like phenotype (B). Treatment with irbesartan could significantly prevent the morphological changes (C). NG: normal
glucose. HG: high glucose. HI+Irb: high glucose + Irbesartan.
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These findings suggest a novel and early mechanism
concerning HG-induced endothelial damage via an
angiotensin II-mediated EndMT, which provides new
insight into the early application of ARB in the protec-
tion of blood vessels and the prevention of organ failure
in diabetes.
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